The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
After its advisory committee voted against AstraZeneca's camizestrant as a treatment for breast cancer in April, the FDA has ...
image: Mafalda Oliveira, Senior Consultant at the Vall d’Hebron University Hospital’s Medical Oncology Department and Clinical Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Breast ...
Phase 3 lidERA evaluates daily oral SERD giredestrant in ER+/HER2- early disease, including subgroup analyses by age and menopausal status after a reported 30% risk reduction. Primary ASCENT-04 data ...
Sean P. Bohen, MD, PhD, Olema Oncology President and CEO While biopharma giants showed mixed results in 2022 trying to treat breast cancer with selective ER degraders (SERDs), a much smaller drug ...
Dr Vidula and Dr Lu describe how selective estrogen receptor degraders (SERDs) differ in their mechanism of action from other therapies for ER+/HER2– metastatic breast cancer and how newer SERDs ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization for Etcamah (AstraZeneca), a next-generation oral selective estrogen ...
SAN ANTONIO -- In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus ...
Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for treating late-stage breast cancer patients. Branded Inluriyo, the second-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results